[go: up one dir, main page]

CO5271716A1 - CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED - Google Patents

CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED

Info

Publication number
CO5271716A1
CO5271716A1 CO00085285A CO00085285A CO5271716A1 CO 5271716 A1 CO5271716 A1 CO 5271716A1 CO 00085285 A CO00085285 A CO 00085285A CO 00085285 A CO00085285 A CO 00085285A CO 5271716 A1 CO5271716 A1 CO 5271716A1
Authority
CO
Colombia
Prior art keywords
crystals
carboxamine
tetrahydroquinoline
replaced
imf
Prior art date
Application number
CO00085285A
Other languages
Spanish (es)
Inventor
Allen Douglas John Meldrum
Anthony Appleton Troy
Robinson Brostrom Lyle
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5271716A1 publication Critical patent/CO5271716A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Se describen formas cristalinas de un inhibidor de CETP, procedimiento preparar los cristales, procedimientos de uso de los cristales y composiciones farmacéuticas que contienen los cristales.<EMI FILE="00085285_1" ID="1" IMF=JPEG >Crystalline forms of a CETP inhibitor, method of preparing the crystals, methods of using the crystals and pharmaceutical compositions containing the crystals are described. <EMI FILE = "00085285_1" ID = "1" IMF = JPEG>

CO00085285A 1999-11-30 2000-11-09 CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED CO5271716A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
CO5271716A1 true CO5271716A1 (en) 2003-04-30

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00085285A CO5271716A1 (en) 1999-11-30 2000-11-09 CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED

Country Status (28)

Country Link
EP (1) EP1246804A1 (en)
JP (1) JP2003515592A (en)
KR (1) KR20020058057A (en)
CN (1) CN1402711A (en)
AP (1) AP2002002531A0 (en)
AU (1) AU1048801A (en)
BG (1) BG106854A (en)
BR (1) BR0015836A (en)
CA (1) CA2392979A1 (en)
CO (1) CO5271716A1 (en)
EA (1) EA200200510A1 (en)
EC (1) ECSP003792A (en)
EE (1) EE200200277A (en)
GT (1) GT200000199A (en)
HU (1) HUP0203521A2 (en)
IL (1) IL149097A0 (en)
IS (1) IS6338A (en)
MA (1) MA26845A1 (en)
MX (1) MXPA02005354A (en)
NO (1) NO20022558L (en)
OA (1) OA12099A (en)
PA (1) PA8506301A1 (en)
PE (1) PE20010904A1 (en)
PL (1) PL355892A1 (en)
TN (1) TNSN00231A1 (en)
TR (1) TR200201446T2 (en)
UY (1) UY26454A1 (en)
WO (1) WO2001040190A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
HUP0400263A2 (en) * 2001-06-21 2005-03-29 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
GT200200170A (en) * 2001-09-28 2003-05-23 PREPARATION OF INHIBITOR OF CETP ANHIDRO
JP2005523262A (en) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming substances
WO2003063822A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
EP1533292B1 (en) 2002-08-30 2007-02-14 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
CA2500582A1 (en) 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
CA2508840A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
KR20050110017A (en) 2003-03-17 2005-11-22 니뽄 다바코 산교 가부시키가이샤 Method for increasing the oral bioavailability of s-'2-(''1-(2-ethylbutyl)cyclohexyl!carbonyl!amino)phenyl!-2-methylpropanethioate
JP2006521344A (en) * 2003-03-28 2006-09-21 ファイザー・プロダクツ・インク 1,2,4-substituted 1,2,3,4-tetrahydro- and 1,2-dihydro-quinoline and 1,2,3,4 as CETP inhibitors for the treatment of atherosclerosis and obesity -Tetrahydro-quinoxaline derivatives
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
WO2005037796A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
CA2562082C (en) * 2004-04-13 2013-06-25 Merck & Co., Inc. Cetp inhibitors for the treatment and prevention of atherosclerosis
KR20070041452A (en) * 2004-06-24 2007-04-18 일라이 릴리 앤드 캄파니 Compounds and methods for treating dyslipidemia
US20070149567A1 (en) * 2004-09-23 2007-06-28 Pfizer Inc Quinoline compounds
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
CA2598133A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (en) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Method for inhibiting lipid absorption and lipid absorption inhibitor
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2008112166A2 (en) 2007-03-09 2008-09-18 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
TWI450896B (en) 2009-06-30 2014-09-01 Lilly Co Eli Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
RU2703192C2 (en) 2014-07-30 2019-10-15 Ф. Хоффманн-Ля Рош Аг Genetic markers for predicting response to therapy by raising hdl level or imitating hdl agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
AU5731098A (en) * 1997-02-03 1998-08-25 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
AU1048801A (en) 2001-06-12
BG106854A (en) 2002-12-29
MA26845A1 (en) 2004-12-20
PL355892A1 (en) 2004-05-31
GT200000199A (en) 2002-05-23
ECSP003792A (en) 2002-04-23
IL149097A0 (en) 2002-11-10
JP2003515592A (en) 2003-05-07
PA8506301A1 (en) 2002-08-26
UY26454A1 (en) 2001-07-31
IS6338A (en) 2002-04-12
KR20020058057A (en) 2002-07-12
TNSN00231A1 (en) 2002-05-30
EP1246804A1 (en) 2002-10-09
OA12099A (en) 2006-05-04
BR0015836A (en) 2002-08-06
NO20022558D0 (en) 2002-05-29
EE200200277A (en) 2003-10-15
PE20010904A1 (en) 2001-09-10
NO20022558L (en) 2002-05-29
AP2002002531A0 (en) 2002-06-30
WO2001040190A1 (en) 2001-06-07
EA200200510A1 (en) 2002-10-31
CA2392979A1 (en) 2001-06-07
TR200201446T2 (en) 2002-11-21
CN1402711A (en) 2003-03-12
HUP0203521A2 (en) 2003-02-28
MXPA02005354A (en) 2002-12-11

Similar Documents

Publication Publication Date Title
CO5271716A1 (en) CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED
MX9302214A (en) DERIVATIVES OF TAXOL AND PROCESS FOR ITS PREPARATION
MX9603050A (en) 1-h-3-arylpyrrolidine-2,4-dione derivatives as pest-control agents.
DK0914119T3 (en) Process for the preparation of solid oral dosage forms of valsartan
DK0788496T3 (en) Inhibitors for the synthesis of apolipoprotein-B
ES2122258T3 (en) 4-AZAESTEROIDS 15 SUBSTITUTED.
TR199801513A2 (en) N- (4-Trifluoromethylphenyl) - 5- methyl-isoxazole-4-carboxamide crystal form.
SE8904298D0 (en) NEW COMPOUNDS
DK293088A (en) DOPAMINE-BETA-HYDROXYLASE INHIBITORS
CO5150178A1 (en) ELETRIPTAN MONOHIDRATE BROMOHYDRATE AND PROCEDURE FOR PREPARATION
SE9902550D0 (en) New crystalline forms
IT1293777B1 (en) PROCESS FOR THE PREPARATION OF TETRAAZAMACROCYCLES
BR9400016A (en) Process for preparing compounds, and compounds
ES2098338T3 (en) HETEROARILMETILBENCENOS.
AP2002002651A0 (en) Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
ES2163001T3 (en) NEW DERIVATIVES OF BORNEOL, PROCEDURE FOR ITS PREPARATION AND ITS PHARMACEUTICAL USE.
DK192890A (en) 24R-SCUMNOL, METHOD OF PREPARING IT AND USING THE SAME
SE9402241D0 (en) Inhibitor
CO5080790A1 (en) ACRIDINE DERIVATIVES AND PROCEDURE FOR THE PREPARATION OF SUCH DERIVATIVES
DK1064857T3 (en) Process for the preparation of compositions containing polyamines
AP2002002493A0 (en) Sodium-hydrogen exchanger type 1 inhibitor crystals.
CO5180571A1 (en) CRYSTALLINE FORM III OF THE N- (4-DIMETHYLAMINONAFTALEN-1 SULPHONYLAMINE) PHENYL) -3-HYDROXI-2,2-DIMETHYLPROPIONAMIDE
PT1007498E (en) METHOD FOR THE MANUFACTURE OF 2-HALOGENOINDANE-1-ONES
DK1124785T3 (en) Process for the preparation of alpha-arylalkanoic acids
BR9711574A (en) Operational mixtures for cutting rocks and using these mixtures.